GlassScriptPhysician profile
Mark R Miller
NPI 1841250842
$2,782.77
in general payments reported to CMS, 2019-2025
28 companies · $343 in 2025
The $343 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $239 · 2020: $120 · 2021: $467 · 2022: $473 · 2023: $463 · 2024: $679 · 2025: $343.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,400 · Education: $83.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,400.43 |
| Education | $83.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,506.59 | 2019-2025 | |
| Janssen Biotech, INC. | $199.63 | 2019-2024 | Stelara, Tremfya |
| Janssen Scientific Affairs, LLC | $140.49 | 2024 | Stelara, Tremfya, Remicade |
| Pfizer INC. | $132.99 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $92.29 | 2020-2025 | Entyvio |
| Shield Therapeutics INC | $73.09 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $70.49 | 2021-2025 | Xifaxan |
| Daiichi Sankyo INC. | $55.53 | 2022-2023 | Injectafer |
| Medtronic, INC. | $55.44 | 2021-2024 | Gi Genius |
| Celgene Corporation | $43.61 | 2021 | |
| Vivus LLC | $41.73 | 2022-2025 | Pancreaze, Qsymia |
| Regeneron Healthcare Solutions, INC. | $40.85 | 2023-2025 | Dupixent |
| Amgen INC. | $39.30 | 2021-2023 | Avsola |
| Allergan, INC. | $37.23 | 2019 | |
| Ardelyx, INC. | $29.02 | 2024 | Ibsrela |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $24.02 | 2024 | |
| Genentech USA, INC. | $23.17 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $22.65 | 2023 | Imfinzi |
| Novo Nordisk INC | $22.25 | 2025 | Wegovy |
| Abbott Laboratories | $18.04 | 2019 | |
| Nestle Healthcare Nutrition INC. | $17.85 | 2021 | |
| Pharmacyclics LLC, An Abbvie Company | $17.52 | 2023 | Imbruvica |
| Ironwood Pharmaceuticals, INC | $17.51 | 2019 | |
| Integra Lifesciences Corporation | $16.31 | 2024 | Acclarent Aera |
| Axonics, INC. | $15.98 | 2023 | Axonics |
| Ferring Pharmaceuticals INC. | $15.41 | 2019 | |
| Alfasigma USA, INC. | $13.78 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$26,479.86 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.